| Bioactivity | ALLM (Calpain inhibitor II) is a potent inhibitor of calpain and cathepsin proteases. ALLM inhibits neuronal cell death and improves chronic neurological function after spinal cord injury (SCI)[1][2]. |
| In Vivo | ALLM (Calpain inhibitor II) (0.5 mg/kg) is injected every 24 h for 5 days after SCI and inhibits the activation of calpain but not that of caspase 3. ALLM prevents this neuronal cell death[2].ALLM (0.05-2.5 mg/kg; i.p.; every 24 h for 1 week) reduces motor disturbances after spinal cord injury (SCI)[2]. Animal Model: |
| Name | ALLM |
| CAS | 110115-07-6 |
| Formula | C19H35N3O4S |
| Molar Mass | 401.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Stangl V, et al. Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J. 2004 Feb;18(2):272-9. [2]. Arataki S, et al. Calpain inhibitors prevent neuronal cell death and ameliorate motor disturbances after compression-induced spinal cord injury in rats. J Neurotrauma. 2005 Mar;22(3):398-406. |